Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:262
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [41] PD-1 and PD-L1 blockade in gastrointestinal malignancies
    Lote, Hazel
    Cafferkey, Catherine
    Chau, Ian
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 893 - 903
  • [42] The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
    Rasyid, Nur Rahmah
    Miskad, Upik Anderiani
    Cangara, Muhammad Husni
    Wahid, Syarifuddin
    Achmad, Djumadi
    Tawali, Suryani
    Mardiati, Mardiati
    CURRENT ONCOLOGY, 2024, 31 (12) : 7476 - 7493
  • [43] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [44] Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
    Shin, Kabsoo
    Kim, Joori
    Park, Se Jun
    Lee, Myung Ah
    Park, Jae Myung
    Choi, Myung-Gyu
    Kang, Donghoon
    Song, Kyo Young
    Lee, Han Hong
    Seo, Ho Seok
    Lee, Sung Hak
    Kim, Bohyun
    Kim, Okran
    Park, Juyeon
    Kang, Nahyeon
    Kim, In-Ho
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [45] Drug response to PD-1/PD-L1 blockade: based on biomarkers
    Chen, Qi
    Li, Tianhe
    Yue, Wentao
    ONCOTARGETS AND THERAPY, 2018, 11 : 4673 - 4683
  • [46] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [47] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    LUNG CANCER, 2016, 99 : 79 - 87
  • [48] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [49] PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
    Wang, Yumeng
    Li, Guiling
    FRONTIERS OF MEDICINE, 2019, 13 (04) : 438 - 450
  • [50] Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
    Chen, Miaomiao
    Zhou, Yuli
    Bao, Kaicheng
    Chen, Siyu
    Song, Guoqing
    Wang, Siliang
    BIODRUGS, 2025, : 427 - 444